|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Samples** | **LOH** | **Tumor Type** | **BRCA status** | **HR genes** | **Mutation detected** | **PD L1** | **TMB** | **MSI** |
| ***1*** | ***Low 9.06 %*** | ***PANCREATIC CANCER*** | ***-*** | ***+*** | ***KRAS|ARID1A|TP53|*** | ***negative|TC <1% IC<1%*** | ***2.84*** | ***MSS*** |
| ***2*** | ***High 24,38%*** | ***ANAPLASTIC ASTROCYTOMA*** | ***-*** | ***+*** | ***IDH1|IDH1|TP53|ATRX|CDK6*** | ***negative|TC<1%, IC<1%*** | ***5.72*** | ***MSS*** |
| ***3*** | ***Low 0%*** | ***Clear cell hidradenocarcinoma*** | ***-*** | ***+*** | ***BAP1|MARCO|TP53|*** | ***positive|TC<1% IC 5%*** | ***5.87*** | ***MSS*** |
| ***4*** | ***High 38,07%*** | ***LEIOMYOSARCOMA*** | ***-*** | ***+*** | ***ATRX|TP53|*** | ***negative|TC<1%, IC<1%*** | ***4.83*** | ***MSS*** |
| ***5*** | ***High 21,92%*** | ***SARCOMA*** | ***-*** | ***+*** | ***ATRX|TP53|TP53|GNA13|SRSF2|*** | ***positive|TC<1%, IC 10%*** | ***5.67*** | ***MSS*** |
| ***6*** | ***High 98.78 %*** | ***SARCOMA*** | ***-*** | ***+*** | ***CHEK2|CASP8|TGFBR2|PBRM1|TP53|*** | ***positive|TC 40%, IC<1%*** | ***6.64*** | ***MSS*** |
| ***7*** | ***Low 3.69 %*** | ***SARCOMA*** | ***-*** | ***+*** | ***ATRX|TP53|*** | ***negative|TC <1% IC<1%*** | ***4.82*** | ***MSS*** |
| ***8*** | ***High 19,46%*** | ***UTERINE SARCOMA*** | ***-*** | ***+*** | ***ATRX|AXIN1|TP53|KMT2B|*** | ***negative|TC<1%, IC<1%*** | ***5.72*** | ***MSS*** |
| ***9*** | ***High 23.6 %*** | ***BRAIN TUMOR*** | ***-*** | ***+*** | ***PTEN|ATRX|TP53|TP53|MYCN|*** | ***negative|TC<1% IC <1%*** | ***2.85*** | ***MSS*** |
| ***10*** | ***High 27.7 %*** | ***BREAST CANCER*** | ***-*** | ***+*** | ***PIK3CA|PIK3CA|ATM|BCOR|RB1|MTOR|TP53|MECOM|TBX3|AURKA|NOTCH4*** | ***-|IC<1%*** | ***12.31*** | ***MSS*** |
| ***11*** | ***Low 9,72%*** | ***BREAST CANCER*** | ***-*** | ***+*** | ***PIK3CA|PIK3CA|FANCL|CDH1|TP53|KMT2C|ERBB2*** | ***-|CPS <1*** | ***8.54*** |  |
| ***12*** | ***High 31.23 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***NRAS|ARID1A|TP53|*** |  | ***10.41*** | ***MSS*** |
| ***13*** | ***Low 2.57 %*** | ***CHOLANGIO-PANCREATIC CANCER*** | ***-*** | ***+*** | ***NRAS|BAP1|TP53|*** | ***negative|TC <1% IC<1%*** | ***3.79*** | ***MSS*** |
| ***14*** | ***Low 9,84%*** | ***COLON CANCER*** | ***-*** | ***+*** | ***TP53|APC|ATRX|*** | ***positive|TC<1%, IC 25%*** | ***6.65*** | ***MSS*** |
| ***15*** | ***High 27,43%*** | ***Colon carcinoma metastasis*** | ***-*** | ***+*** | ***APC|TP53|ARID1A|*** | ***-|*** | ***9.64*** | ***MSS*** |
| ***16*** | ***High 36,6%*** | ***Endometrial Cancer*** | ***-*** | ***+*** | ***CTCF|ARID1A|PTEN|CTNNB1|TP53|*** | ***negative|TC<1% IC<1%*** | ***12.32*** | ***MSS*** |
| ***17*** | **High 30.57 %** | **GASTRIC CANCER** | **-** | **+** | **ARID1A|TP53|** | **negative|CPS <1** | **9.53** | **MSS** |
| ***18*** | **High 41,8%** | **GASTRIC CANCER** | **-** | **+** | **RAD50|TP53|ERBB2|MET|MCL1|TOP2A|H3C2|RARA|RPS6KB1** | **negative|CPS <1** | **4.75** | **MSS** |
| ***19*** | ***High 46,09%*** | ***GLIOBLASTOMA*** | ***-*** | ***+*** | ***ATRX|TP53|H3F3A|EGFR|CDK6|*** | ***negative|TC<1%, IC<1%*** | ***5.06*** | ***MSS*** |
| ***20*** | ***High 42,75%*** | ***LUNG CANCER*** | ***-*** | ***+*** | ***KRAS|KRAS|TP53|BARD1|POLE|*** | ***positive|TPS>50%*** | ***13.27*** | ***-*** |
| ***21*** | ***Low 5,47%*** | ***METASTATIC LUNG CANCER*** | ***-*** | ***+*** | ***ATM|CDKN2A|RBM10|TP53|*** | ***-|*** | ***21.83*** | ***MSS*** |
| ***22*** | ***High 38,04%*** | ***OVARIAN CANCER*** | ***-*** | ***+*** | ***RAD51C|TP53|TSC2|RASA1|*** |  | ***10.44*** | ***MSS*** |
| ***23*** | ***Low 12,5%*** | ***OVARIAN CANCER*** | ***-*** | ***+*** | ***RAD51B|RAD50|TP53|CUL4A|GPS2|*** |  | ***1.9*** | ***MSS*** |
| ***24*** | ***Low 4,74%*** | ***RECTAL CANCER*** | ***-*** | ***+*** | ***KRAS|KRAS|SMAD2|ARID1A|TP53|APC|*** | ***positive|TC<1%, IC 3%*** | ***1.9*** | ***MSS*** |
| ***25*** | ***Low 15,36%*** | ***UROTHELIAL CANCER*** | ***-*** | ***+*** | ***ATM|MSH2|TP53|CTCF|*** | ***positive|CPS 40*** | ***20.13*** | ***MSIH*** |
| ***26*** | ***High 42.67 %*** | ***PANCREATIC CANCER*** | ***-*** | ***+*** | ***MRE11A|KRAS|ID3|MCL1|ELF3|H3-3A|PCBP1|H3C2|H1-4|PIM1|MET|FANCF|CDKN1B|KNSTRN|GNA13|H3-3B|*** | ***negative|TC<1% IC<1%*** | ***2.85*** | ***MSS*** |
| ***27*** | ***High 62,57%*** | ***PANCREATIC CANCER*** | ***-*** | ***+*** | ***NBN|FGFR1|TERT|*** | ***negative|TC<1%, IC<1%*** | ***3.8*** | ***MSS*** |
| ***28*** | ***High 66,58%*** | ***PANCREATIC CANCER*** | ***-*** | ***+*** | ***HRAS|ATRX|NOTCH4|*** | ***negative|TC<1%, IC<1%*** | ***12.41*** | ***MSS*** |
| ***29*** | ***Low 7,63*** | ***PANCREATIC CANCER*** | ***-*** | ***+*** | ***BLM|KRAS|NOTCH2|*** | ***negative|TC<1% IC<1%*** | ***1.94*** | ***MSS*** |
| ***30*** | ***Low 10,99%*** | ***Adenocystic Ca of Salivary Glands*** | ***-*** | ***+*** | ***RAD50|KIT|PDGFRA|*** | ***negative|CPS<1, TPS<1%*** | ***fail*** | ***MSS*** |
| ***31*** | ***Low 0 %*** | ***ADENOID CYSTIC CARCINOMA OF SALIVARY GLAND*** | ***-*** | ***+*** | ***BLM|MYB fusion|PCBP1|*** | ***negative|CPS <1 , TPS<1%*** | ***0*** | ***MSS*** |
| ***32*** | ***Low 0%*** | ***Atypical carcinoid tumor*** | ***-*** | ***+*** | ***YES1|FANCM|PMS2|XRCC2|*** | ***negative|TPS<1%*** | ***3.81*** | ***MSS*** |
| ***33*** | **High 48,77%** | **CHOROID PLEXUS PAPILLOMA** | **-** | **+** | **MRE11A|FGFR2|** | **negative|TC<1%, IC<1%** | **4.75** | **MSS** |
| ***34*** | ***High 26,49%*** | ***TONSIL CA*** | ***-*** | ***+*** | ***RAD50|PIK3CA|ERBB2|*** | ***positive|CPS 3,8 TPS<1%*** | ***10.84*** | ***MSS*** |
| ***35*** | ***High 16,07%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***+*** | ***MLH1|ARID1A|DPYD|*** | ***negative|TC<1% IC<1%*** | ***17.22*** | ***MSS*** |
| ***36*** | ***Low 0%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***+*** | ***PALB2|PIK3CA|*** | ***negative|TC<1%, IC<1%*** | ***17.09*** | ***MSS*** |
| ***37*** | **High 25,81%** | ***LIVER CANCER*** | **-** | **+** | **KRAS|ATR|ARID2|** | **negative|TC<1%, IC<1%** | **1.9** | **MSS** |
| ***38*** | ***Low 3.33 %*** | ***SARCOMA*** | ***-*** | ***+*** | ***ARID1A|CTNNB1|B2M|SMARCA4|*** | ***positive|TC<1% IC 10%*** | ***6.72*** | ***MSS*** |
| ***39*** | ***Low 13,57*** | ***BLADDER CANCER*** | ***-*** | ***+*** | ***NBN|TP53*** | ***positive|CPS 12,72*** | ***0*** | ***MSS*** |
| ***40*** | ***Low 0%*** | ***BREAST CANCER*** | ***-*** | ***+*** | ***PIK3CA|PIK3CA|BARD1|*** |  | ***4.75*** | ***MSS*** |
| ***41*** | ***Low 1,27%*** | ***BREAST CANCER*** | ***-*** | ***+*** | ***ATM|*** |  | ***0.97*** | ***MSS*** |
| ***42*** | ***Low 12.88 %*** | ***BREAST CANCER*** | ***-*** | ***+*** | ***ESR1|ESR1|AKT1|ESR1 fusion|CCND1|FGF19|FGF4|FGF3|CDK4|MDM2|RNF43|RPS6KB1|PPM1D|BRIP1|*** | ***-|CPS<1*** | ***2.85*** | ***MSS*** |
| ***43*** | ***High 20,86*** | ***Ca Cervical*** | ***-*** | ***+*** | ***AXIN1|FANCM|PIK3CA|IL7R|*** | ***positive|CPS 16*** | ***7.73*** | ***MSS*** |
| ***44*** | ***Low 15,27%*** | ***CERVICAL CANCER*** | ***-*** | ***+*** | ***PIK3CA|PIK3CA|MSH2|MSH2|PTEN|CDKN2A|ARID1A|ARID1A|CTNNB1|CTNNB1|DPYD|KMT2B|KMT2D|MAP3K1|PPP2R1A|ARID1B|*** | ***positive|13,12*** | ***24.94*** | ***MSIH*** |
| ***45*** | ***High 31.71 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***BAP1|FGFR2 fusion|*** | ***negative|TC <1% IC <1%*** | ***0*** | ***MSS*** |
| ***46*** | ***High 42,55%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***PALB2|ARID1A|*** | ***positive|TC<1% IC 5%*** | ***1.97*** | ***MSS*** |
| ***47*** | ***Low 0%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***IDH2|BAP1|NOTCH2|DDR2|TP63|CTNND2|ADAMTS12|IL7R|YAP1|AR|*** | ***negative|TC <1% IC<1%*** | ***5.7*** | ***MSS*** |
| ***48*** | ***Low 0%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***FANCM|*** | ***positive|TC<1%, IC 2%*** | ***2.84*** | ***MSS*** |
| ***49*** | ***Low 11,66%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***+*** | ***IDH1EPHA2|ARID1A*** | ***positive|TC<1%, IC 2%*** | ***5.67*** | ***MSS*** |
| ***50*** | ***Low 0%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***+*** | ***PTEN|PTEN|ARID1A|PIK3R1|CTNNB1|*** | ***positive|TC<1%, IC 20%*** | ***7.72*** | ***MSS*** |
| ***51*** | ***Low 0%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***+*** | ***PTEN|KRAS|CTCF|ARID1A*** | ***positive|TC<1% IC 5%*** | ***10.52*** | ***MSIH*** |
| ***52*** | ***Low 2,61%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***+*** | ***PTEN|ARID1A*** | ***negative|TC<1%, IC<1%*** | ***6.64*** | ***MSS*** |
| ***53*** | **Low 0%** | **GASTRIC CANCER** | **-** | **+** | **ATM|CDH1|** | **negative|CPS <1** | **3.8** | **MSS** |
| ***54*** | **Low 0%** | **GASTRIC CANCER** | **-** | **+** | **ATM|ELF3|ELF3|ASXL2|** | **negative|CPS 0,5** | **8.57** | **MSS** |
| ***55*** | **Low 0%** | **GASTRIC CANCER** | **-** | **+** | **ARID1A|PIK3CA|MSH3|SMAD4|** | **positive|CPS 45** | **2.86** | **MSS** |
| ***56*** | ***Low 5,03%*** | ***Glioblastoma*** | ***-*** | ***+*** | ***FANCL|RUNX1|TERT|*** | ***negative|TC<1% IC<1%*** | ***16.56*** | ***MSS*** |
| ***57*** | ***High 21,34%*** | ***LUNG CANCER*** | ***-*** | ***+*** | ***FANCM|RB1|EP300|PTEN*** | ***negative|TPS<1%*** | ***9.47*** | ***MSS*** |
| ***58*** | ***Low 6.01 %*** | ***LUNG CANCER*** | ***-*** | ***+*** | ***FANCM|SDHA|SLX4|CDKN2A|SMARCA4|ZMYM3|*** | ***negative|TPS<1%*** | ***24*** | ***MSS*** |
| ***59*** | ***Low 11,27*** | ***LUNG CANCER*** | ***-*** | ***+*** | ***KRAS|STK11|STK11|ATM|CDKN2A|KEAP1|MYC|*** |  | ***13.25*** | ***MSS*** |
| ***60*** | ***High 69,59%*** | ***OVARIAN CANCER*** | ***-*** | ***+*** | ***ATR|*** | ***negative|TC<1%, IC<1%*** | ***12.29*** | ***MSS*** |
| ***61*** | ***High 19,81%*** | ***PROSTATE CANCER*** | ***-*** | ***+*** | ***CHEK2|CHEK2|ERG fusion|*** | ***negative|TC<1% IC<1%*** | ***2.91*** | ***MSS*** |
| ***62*** | ***Low 12,12%*** | ***PROSTATE CANCER*** | ***-*** | ***+*** | ***ATM|ATM*** | ***negative|TC<1%, IC<1%*** | ***0*** | ***MSS*** |
| ***63*** | ***High 24,96%*** | ***UROTHELIAL CANCER*** | ***-*** | ***+*** | ***TP53|TP53|ELF3|NF2|ARID1A|RAF1|VHL|FANCD2|*** | ***positive|CPS 36*** | ***6.71*** | ***MSS*** |
| ***64*** | ***Low 9.36%*** | ***UROTHELIAL CARCINOMA*** | ***-*** | ***+*** | ***HRAS|PIK3CA|CREBBP|ARID1A|TAP2|RAF1|CTNNB1|*** | ***negative|CPS 5*** | ***19.94*** | ***MSS*** |
| ***65*** | ***High 19.62 %*** | ***NEUROENDOCRINE PANCREATIC TUMOR*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC <1%IC<1%*** | ***1.89*** | ***MSS*** |
| ***66*** | ***High 16,16%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***TP53*** | ***negative|TC<1%, IC<1%*** | ***4.74*** | ***MSS*** |
| ***67*** | ***High 20.65 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4|FAT1|PARP2|*** | ***negative|TC<1% IC<1%*** | ***7.57*** | ***MSS*** |
| ***68*** | ***High 23,21%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53*** | ***positive|TC<1% IC 10%*** | ***7.59*** | ***MSS*** |
| ***69*** | ***High 24,18%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***IDH1|MAP2K1|EPHA2|*** | ***negative|TC<1%, IC<1%*** | ***3.8*** | ***MSS*** |
| ***70*** | ***High 25,42%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4|SMARCA4|*** | ***negative|TC<1%, IC<1%*** | ***3.82*** | ***MSS*** |
| ***71*** | ***High 26,46%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4*** | ***negative|TC<1%, IC<1%*** | ***4.74*** | ***MSS*** |
| ***72*** | ***High 27,76*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4|TP53|STAG2|ABRAXAS1|*** | ***negative|TC<1%, IC<1%*** | ***10.44*** | ***MSS*** |
| ***73*** | ***High 27,82%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|ASXL1|KRAS|*** | ***positive|TC 30%, IC 15%*** | ***7.59*** | ***MSS*** |
| ***74*** | ***High 28,13%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***TP53|BRAF fusion*** | ***positive|TC<1%, IC 10%*** | ***3.84*** | ***MSS*** |
| ***75*** | ***High 30,51%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS*** | ***negative|TC<1%, IC<1%*** | ***17.96*** | ***MSS*** |
| ***76*** | ***High 32,61%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|MUTYH|TP53|*** | ***negative|TC<1%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***77*** | ***High 32,66%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|SF3B1|AURKC|MYC*** | ***positive|TC 2%, IC 1%*** | ***2.85*** | ***MSS*** |
| ***78*** | ***High 36.49 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC<1% IC 5%*** | ***1.89*** | ***MSS*** |
| ***79*** | ***High 37,87%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC<1%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***80*** | ***High 38.87 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SF3B1|TP53|BCL2L12|*** | ***positive|TC 20% IC 5%*** | ***3.79*** | ***MSS*** |
| ***81*** | ***High 43,49%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|CCND3|*** | ***negative|TC<1%, IC<1%*** | ***5.75*** | ***MSS*** |
| ***82*** | ***High 22,76%*** | ***ADRENAL GLAND ADENOCARCINOMA*** | ***-*** | ***-*** | ***TERT|CTNND2|*** | ***negative|TC<1%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***83*** | ***High 31.92 %*** | ***AMPULLA OF VATER CARCINOMA*** | ***-*** | ***-*** | ***TP53*** | ***negative|TC <1% IC<1%*** | ***4.76*** | ***MSS*** |
| ***84*** | ***High 39.07 %*** | ***AMPULLA OF VATER CARCINOMA*** | ***-*** | ***-*** | ***ELF3|TP53|JAK3|*** | ***positive|TC <1% IC 2%*** | ***4.73*** | ***MSS*** |
| ***85*** | ***High 22,06%*** | ***ANAPLASTIC THYROID CANCER*** | ***-*** | ***-*** | ***CCNE|*** | ***positive|TC 20%, IC 2%*** | ***2.85*** | ***MSS*** |
| ***86*** | ***High 17,71%*** | ***Appendix mucinosis adenocarcinoma*** | ***-*** | ***-*** | ***KRAS|TP53*** | ***negative|TC<1% IC<1%*** | ***6.84*** | ***MSS*** |
| ***87*** | ***High 44,95%*** | ***Ca Tongue*** | ***-*** | ***-*** | ***TERT|TP53|NOTCH1*** | ***positive|CPS 6,1 TPS<1%*** | ***2.86*** | ***MSS*** |
| ***88*** | ***High 37,06%*** | ***Cardioesophageal adenocarcinoma*** | ***-*** | ***-*** | ***TP53|XRCC3|*** | ***negative|CPS<1*** | ***10.53*** | ***MSS*** |
| ***89*** | ***High 20%*** | ***ESOPHAGEAL CANCER*** | ***-*** | ***-*** | ***CDKN2A|TP53|*** | ***positive|CPS 48*** | ***3.86*** | ***MSS*** |
| ***90*** | ***High 52,77%*** | ***GALLBLADDER CA*** | ***-*** | ***-*** | ***SMAD4|TP53|*** | ***positive|TC<1%, IC 25%*** | ***9.54*** | ***MSS*** |
| ***91*** | ***High 35.76 %*** | ***HEPATOCELLULAR CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC <1% IC<1%*** | ***2.84*** | ***MSS*** |
| ***92*** | ***High 30,27%*** | ***HEPATOPCELLULAR CARCINOMA*** | ***-*** | ***-*** | ***TP53|LARP4B|ARID1B|*** | ***positive|TC 15%, IC 20%*** | ***9.53*** | ***MSS*** |
| ***93*** | ***High 39,95%*** | ***MELANOMA*** | ***-*** | ***-*** | ***NF1|HRAS|BRAF|TERT|*** |  | ***41.1*** | ***MSS*** |
| ***94*** | ***High 54,97%*** | ***MIXED GERM CELL TUMOR*** | ***-*** | ***-*** | ***CDKN2A|TP53*** | ***negative|TC<1%, IC<1%*** | ***4.91*** | ***MSS*** |
| ***95*** | ***High 25,29%*** | ***PAPILLARY RENAL CARCINOMA*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC<1%, IC 5%*** | ***2.84*** | ***MSS*** |
| ***96*** | ***High 32,32%*** | ***PENILE CANCER*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC<1%, IC 15%*** | ***2.84*** | ***MSS*** |
| ***97*** | ***High 40.56 %*** | ***SALIVARY GLAND CANCER*** | ***-*** | ***-*** | ***MYC|*** | ***positive|CPS 7,5 TPS<1%*** | ***1.93*** | ***MSS*** |
| ***98*** | ***High 19,19*** | ***TESTİCULAR TUMOR ADENOCANCER WİTH NEUROENDOCRİNE DİFFERENTİATİON*** | ***-*** | ***-*** | ***CTNNB1*** | ***negative|TC<1% IC<1%*** | ***4.82*** | ***MSS*** |
| ***99*** | ***High 17,35%*** | ***THYMIC CANCER*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC 30%, IC<1%*** | ***2.85*** | ***MSS*** |
| ***100*** | ***High 34,1%*** | ***UKNOWN PRIMARY*** | ***-*** | ***-*** | ***TP53|*** | ***negative|TC<1%, IC<1%*** | ***2.82*** | ***MSS*** |
| ***101*** | ***High 40,4%*** | ***UNKNOWN*** | ***-*** | ***-*** | ***KRAS|CAPZA2(1) - MET(2) fusion|FGF23|CCND2|*** | ***positive|TC<1% IC 10%*** | ***3.81*** | ***MSS*** |
| ***102*** | ***High 17,04%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***STK11|STK11|MDM2|YAP1|*** | ***positive|TC 15%, IC 10%*** | ***4.75*** | ***MSS*** |
| ***103*** | ***High 25,36%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***GNAS|ZNF217|MDM2|CDK4|ERBB3|*** | ***negative|TC<1%, IC<1%*** | ***3.81*** | ***MSS*** |
| ***104*** | ***High 26.9 %*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***CDKN2A|PTEN|TERT|TP53|CCND1|FGF19|FGF4|FGF3|*** | ***negative|TC<1% IC<1%*** | ***4.77*** | ***MSS*** |
| ***105*** | ***High 28.78 %*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***TP53|EGFR*** | ***negative|TC <1% IC<1%*** | ***2.86*** | ***MSS*** |
| ***106*** | ***High 29,16%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1%, IC<1%*** | ***3.88*** | ***MSS*** |
| ***107*** | ***High 34.96 %*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***KRAS|KRAS|BRAF|KEAP1|TP53|TP53|KRAS|*** | ***negative|TC <1% IC<1%*** | ***20.25*** | ***MSS*** |
| ***108*** | ***High 41,35%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***NOTCH4|*** | ***negative|TC<1%, IC<1%*** | ***2.86*** | ***MSS*** |
| ***109*** | **High 19,26%** | ***LIVER CANCER*** | **-** | **-** | **TP53|RB1|** | **negative|TC<1%, IC<1%** | **6.65** | **MSS** |
| ***110*** | **High 33,71%** | ***LIVER CANCER*** | **-** | **-** | **KRAS|TP53|FBXW7|MTOR|** | **negative|TC<1%, IC<1%** | **1.9** | **MSS** |
| ***111*** | ***High 27,3%*** | ***CHONDROSARCOMA*** | ***-*** | ***-*** | ***IDH1|KRAS|*** | ***negative|TC<1%, IC<1%*** | ***1.89*** | ***MSS*** |
| ***112*** | ***High 91,2%*** | ***CHONDROSARCOMA*** | ***-*** | ***-*** | ***MLH1|RB1|NOTCH2*** | ***negative|TC<1%, IC<1%*** | ***6.64*** | ***MSS*** |
| ***113*** | ***High 21.31 %*** | ***FOLLICULAR DENDRITIC CELL SARCOMA*** |  ***-***  | ***-*** | ***AURKA*** | ***negative|TC<1% IC<1%*** | ***2.89*** | ***MSS*** |
| ***114*** | ***High 33,52%*** | ***Leiomyosarcoma*** | ***-*** | ***-*** | ***SETD2|TP53|TP53|*** | ***negative|TC<1% IC<1%*** | ***6.88*** | ***MSS*** |
| ***115*** | ***High 39,07%*** | ***LEIOMYOSARCOMA*** | ***-*** | ***-*** | ***RB1|RAD54L|*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***116*** | ***High 59,89%*** | ***LEIOMYOSARCOMA*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC 2%, IC 20%*** | ***11.36*** | ***MSS*** |
| ***117*** | ***High 99%*** | ***LIPOSARCOMA*** | ***-*** | ***-*** | ***NF1|NF1|*** | ***positive|TC<1%, IC 15%*** | ***9.57*** | ***MSS*** |
| ***118*** | ***High 31.53%*** | ***MESENTERIC LEIOMYOSARCOMA*** | ***-*** | ***-*** | ***RB1|TP53|*** | ***negative|TC<1% IC<1%*** | ***10.54*** | ***MSS*** |
| ***119*** | ***High 20,05%*** | ***SARCOMA*** | ***-*** | ***-*** | ***IDH1|MUTYH|KDM6A|MGA|*** | ***positive|TC<1%, IC 10%*** | ***5.68*** | ***MSS*** |
| ***120*** | ***High 43.78 %*** | ***SARCOMA*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC 20% IC 10%*** | ***2.85*** | ***MSS*** |
| ***121*** | ***High 46,06%*** | ***SARCOMATOID CARCINOMA*** | ***-*** | ***-*** | ***KRAS|TP53|RB1|CDH10|AKT2*** | ***positive|TC>50%, IC 10%*** | ***14.34*** | ***MSS*** |
| ***122*** | ***High 20.8 %*** | ***UTERINE LEIOMYOSARCOMA*** | ***-*** | ***-*** | ***FBXW7|TP53|*** | ***negative|TC <1% IC<1%*** | ***3.79*** | ***MSS*** |
| ***123*** | ***High 25.29%*** | ***Leiomyosarcoma*** | ***-*** | ***-*** | ***TP53|MAP2K4|*** | ***negative|TC<1% IC<1%*** | ***0.95*** | ***MSS*** |
| ***124*** | ***High 18,15%*** | ***BRAIN TUMOR*** | ***-*** | ***-*** | ***TERT|EGFR|*** | ***positive|TC<1%, IC 2%*** | ***6.66*** | ***MSS*** |
| ***125*** | ***High 20.19 %*** | ***BRAIN TUMOR*** | ***-*** | ***-*** | ***IDH1|IDH1|TERT|*** | ***negative|TC <1% IC<1%*** | ***4.74*** | ***MSS*** |
| ***126*** | ***High 24,04%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***TP53|CCNE|MYC*** | ***negative|CPS 7*** | ***4.74*** | ***MSS*** |
| ***127*** | ***High 49,77%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***CCND3|CDK6|MDM2|FGFR1|*** | ***positive|CPS 8*** | ***5.74*** | ***MSS*** |
| ***128*** | ***High 17,43%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|CPS 8*** | ***4.76*** | ***MSS*** |
| ***129*** | ***High 20.88 %*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***KDM5C|TP53|IKBKB|*** | ***positive|CPS 14*** | ***0.95*** | ***MSS*** |
| ***130*** | ***High 21,23%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***TP53|*** |  | ***0*** | ***MSS*** |
| ***131*** | ***High 21,35%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***TP53|MYC|*** | ***negative|CPS<1*** | ***14.42*** | ***MSS*** |
| ***132*** | ***High 26,3%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***PIK3CA|ESR1|ESR1|KRAS|CDH1|DPYD|KMT2C|*** | ***-|CPS 1,7*** | ***10.43*** | ***MSS*** |
| ***133*** | ***High 36,16%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***TP53|ERBB2|*** | ***-|CPS <1*** | ***9.55*** | ***MSS*** |
| ***134*** | ***High 37.63 %*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***MUTYH|KMT2C|PTEN|TP53|H3C2|ETV6|*** | ***positive|CPS 42*** | ***9.51*** | ***MSS*** |
| ***135*** | ***High 40,44%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***TP53|FGFR1|*** |  | ***5.72*** | ***MSS*** |
| ***136*** | ***High 50,34%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***MUTYH |TP53|MCL1|MYC*** | ***negative|CPS 0,8*** | ***22.13*** | ***MSS*** |
| ***137*** | ***High 58,3%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***PIK3CA|PIK3CA|PTEN|CCND1|FGF4|FGF3|FGF19|AURKA|*** | ***negative|CPS<1*** | ***14.19*** | ***MSS*** |
| ***138*** | ***High 60,28*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***ESR1|ESR1|TSC1|JAK1|*** | ***-|CPS 26*** | ***3.79*** | ***MSS*** |
| ***139*** | ***High 33,96%*** | ***CERVICAL CANCER*** | ***-*** | ***-*** | ***MLH1|DDX3X|KMT2D|STAT5B|FBXW7|TGFBR2|*** | ***positive|CPS 26*** | ***11.56*** |  |
| ***140*** | ***High 19,35%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***TP53|MAPK1|PDCD1LG2|IL7R|*** | ***positive|TC 15%, IC 5%*** | ***3.94*** | ***MSS*** |
| ***141*** | ***High 20,94*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1*** | ***negative|TC<1%, IC<1%*** | ***4.75*** | ***MSS*** |
| ***142*** | ***High 20.56 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1|IDH1|IDH1*** | ***positive|TC<1% IC 10%*** | ***3.79*** | ***MSS*** |
| ***143*** | ***High 28.25 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***DPYD*** |  | ***2.85*** | ***MSS*** |
| ***144*** | ***High 32.68 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***APC|TAP2|TP53|CCNE1|ZNF536|*** | ***positive|TC <1% IC 3%*** | ***5.7*** | ***MSS*** |
| ***145*** | ***High 33.85 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC <1%*** | ***2.87*** | ***MSS*** |
| ***146*** | ***High 35,96%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1KRAS|*** | ***positive|TC 20%, IC<1%*** | ***1.89*** | ***MSS*** |
| ***147*** | ***High 37,23*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***CTNNB1|TP53|ELF3|EGFR|CCND3|*** | ***negative|TC <1% IC<1%*** | ***7.58*** | ***MSS*** |
| ***148*** | ***High 37,59%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1%, IC<1%*** | ***2.86*** | ***MSS*** |
| ***149*** | ***High 56,14%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1FGFR2|MTOR|*** | ***negative|TC<1%, IC<1%*** | ***1.89*** | ***MSS*** |
| ***150*** | ***High 17.93 %*** | ***COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|APC|TP53|*** | ***positive|TC <1% IC 5%*** | ***6.7*** | ***MSS*** |
| ***151*** | ***High 22,3%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***APC|TP53|*** | ***positive|TC<1%, IC 10%*** | ***4.75*** | ***MSS*** |
| ***152*** | ***High 26.49 %*** | ***COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|APC|*** | ***negative|TC<1% IC<1%*** | ***7.57*** | ***MSS*** |
| ***153*** | ***High 30,96%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***APC|SMAD4||*** | ***positive|TC<1%, IC 10%*** | ***5.79*** | ***MSS*** |
| ***154*** | ***High 33,3%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***APC|*** | ***negative|TC<1%, IC<1%*** | ***4.75*** | ***MSS*** |
| ***155*** | ***High 34,61%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|APC|PIK3R1|TP53|*** | ***negative|TC<1%, IC<1%*** | ***1.95*** | ***MSS*** |
| ***156*** | ***High 37,61%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***NF1|NF1|TP53|RNF43||*** | ***negative|TC<1%, IC<1%*** | ***3.78*** | ***MSS*** |
| ***157*** | ***High 39,09%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***AMER1|APC|TP53|BRAF||*** | ***negative|TC<1%, IC<1%*** |  | ***MSS*** |
| ***158*** | ***High 25,22%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***NRAS|TP53|APC|APC|*** | ***positive|TC<1%, IC 10%*** | ***8.93*** | ***MSS*** |
| ***159*** | ***High 35,95%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|APC|TP53|*** | ***negative|TC<1% IC<1%*** | ***5.76*** | ***MSS*** |
| ***160*** | ***High 20,23%*** | ***COMBINED HEPATOCELLULAR CARCINOMA-CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***KIT|TP53*** | ***negative|TC<1%, IC<1%*** | ***5.67*** | ***MSS*** |
| ***161*** | ***High 19,76%*** | ***Endometrial Cancer*** | ***-*** | ***-*** | ***PTEN|PIK3CA|CTNNB1|*** | ***negative|TC<1% IC<1%*** | ***10.39*** | ***MSS*** |
| ***162*** | ***High 31.89 %*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***PIK3CA|TP53*** | ***negative|TC<1% IC<1%*** | ***5.68*** | ***MSS*** |
| ***163*** | ***High 68%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***TP53|MUTYH|KEAP1|ERBB2|CCNE1|*** | ***positive|TC<1%, IC 10%*** | ***1.9*** | ***MSS*** |
| ***164*** | ***High 18.17 %*** | ***ENDOMETRIAL GIST*** | ***-*** | ***-*** | ***KIT|RB1*** | ***positive|TC 10% IC 15%*** | ***6.64*** | ***MSS*** |
| ***165*** | **High 18,44%** | **GASTRIC CANCER** | **-** | **-** | **APC|TP53|** | **positive|CPS 68** | **13.47** | **MSS** |
| ***166*** | **High 22.29%** | **GASTRIC CANCER** | **-** | **-** | **KRAS|CDKN2A|SMAD4|TP53** | **positive|CPS 5,3** | **8.48** | **MSS** |
| ***167*** | **High 35,54%** | **GASTRIC CANCER** | **-** | **-** | **TP53|MET fusion|MET|FGFR2|FGF19|CCND1|** | **positive|CPS 11** | **6.68** | **MSS** |
| ***168*** | **High 35,87%** | **GASTROESOPHAGEAL JUNCTION CA** | **-** | **-** | **TP53|KRAS|SLCO1B3|** | **-|CPS <1** | **3.78** | **MSS** |
| ***169*** | **High 16,06%** | **GASTROINTENSTINAL STROMAL TUMOR** | **-** | **-** | **EPHA2|** | **negative|TC<1%, IC<1%** | **7.64** | **MSS** |
| ***170*** | **High 17.36 %** | **GASTROINTESTINAL STROMAL TUMOR** | **-** | **-** | **KIT** |  | **3.79** | **MSS** |
| ***171*** | **High 20.5 %** | **GASTROINTESTINAL STROMAL TUMOR** | **-** | **-** | **KIT|MGA|** | **negative|TC <1% IC<1%** | **1.89** | **MSS** |
| ***172*** | **High 38,25%** | **GASTROINTESTINAL STROMAL TUMOR** | **-** | **-** | **KIT|KIT|** | **negative|TC<1%, IC<1%** | **6.67** | **MSS** |
| ***173*** | ***High 20,34%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***TP53|TERT|*** | ***negative|TC<1%, IC<1%*** | ***2.88*** | ***MSS*** |
| ***174*** | ***High 27,2%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***TP53|TERT|*** | ***negative|TC<1%, IC<1%*** | ***0*** | ***MSS*** |
| ***175*** | ***High 63.23%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***TERT|*** | ***negative|TC<1% IC<1%*** | ***6.63*** | ***MSS*** |
| ***176*** | ***High 28,25%*** | ***LUNG*** | ***-*** | ***-*** | ***RET fusion|RET fusion|MDM2|*** | ***negative|TPS<1%*** | ***2.85*** | ***MSS*** |
| ***177*** | ***High 16,6%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|STK11|STK11|*** | ***negative|TPS<1%*** | ***8.59*** | ***MSS*** |
| ***178*** | ***High 22,1%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***ERCC2|RET fusion|RET fusion|MDM2|FGF19|CCND1|FGF4|*** | ***negative|TPS<1%*** | ***4.79*** | ***MSS*** |
| ***179*** | ***High 22,77%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***CTNNB1|*** | ***negative|TPS<1%*** | ***1.9*** | ***MSS*** |
| ***180*** | ***High 22.9*** | ***Lung Cancer*** | ***-*** | ***-*** | ***RPL5|ALK fusion|MYC|*** | ***positive|>50%*** | ***3.8*** | ***MSS*** |
| ***181*** | ***High 26,78%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|STK11|STK11|PBRM1|KRAS|CCND2|ETV6|RAD52|CD163||*** | ***negative|TPS<1%*** | ***9.67*** | ***MSS*** |
| ***182*** | ***High 28.46%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***RB1|PPP6C|NCOR1|TP53|TP53|H3C2|H2BC5|ERCC1|RRM1|*** | ***negative|TPS <1%*** | ***7.59*** | ***MSS*** |
| ***183*** | ***High 28,96%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***SMAD4|TP53|ARID2|RBM10|*** | ***positive|TPS 30%*** | ***3.79*** | ***MSS*** |
| ***184*** | ***High 29,66%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***NRAS|SMARCA4|CTNNB1|PTPRT|XRCC2|*** | ***negative|TPS<1%*** | ***14.24*** | ***MSS*** |
| ***185*** | ***High 33.53%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***TP53|NOTCH1|NOTHC2|KMT2D|MYCL|*** | ***negative|TPS<1%*** | ***17.16*** | ***MSS*** |
| ***186*** | ***High 44,32%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***STK11|STK11|KMT2D|*** | ***negative|TPS<1%*** | ***6.63*** | ***MSS*** |
| ***187*** | ***High 45%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***MGA|TP53|*** | ***positive|TPS>50%*** | ***4.82*** | ***MSS*** |
| ***188*** | ***High 47,29%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***TP53|CDKN2A|CUL4A|*** | ***positive|TPS>50%*** | ***8.52*** | ***MSS*** |
| ***189*** | ***High 50,43%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***TP53|TP53|NFE2L2|CDKN2A|FGF19|CCND1|FGF3|PIK3CA|MECOM|*** | ***negative|TPS<1%*** | ***17.07*** | ***MSS*** |
| ***190*** | ***High 60,4%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***TP53|SMARCA4|MET|MET|FGF4|FGF19|CCND1|RRM1|BRCA1|*** | ***positive|TPS 30%*** | ***6.64*** | ***MSS*** |
| ***191*** | ***High 62,45%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***EGFR|EGFR|EGFR|EGFR|EGFR|TP53|*** |  | ***5.73*** | ***MSS*** |
| ***192*** | ***High 63.35 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***EGFR|PIK3CA|SMAD4|TP53|*** |  | ***5.69*** | ***MSS*** |
| ***193*** | ***High 40,96%*** | ***Metastatic Breast Cancer*** | ***-*** | ***-*** | ***FGFR1|TP53|NTRK3 fusion|*** | ***-|*** | ***3.81*** | ***MSS*** |
| ***194*** | ***High 49,8%*** | ***METASTATIC BREAST CANCER*** | ***-*** | ***-*** | ***TP53|*** | ***positive|IC 25%*** | ***5.69*** | ***MSS*** |
| ***195*** | ***High 68.82 %*** | ***METASTATIC BREAST CANCER*** | ***-*** | ***-*** | ***ESR1|ESR1|GATA3|*** | ***negative|CPS<1*** | ***3.96*** | ***MSS*** |
| ***196*** | ***High 16,63%*** | ***METASTATIC COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|APC|PIK3R1|*** | ***negative|TC<1% IC<1%*** | ***8.56*** | ***MSS*** |
| ***197*** | ***High 49.5 %*** | ***METASTATIC COLON CANCER*** | ***-*** | ***-*** | ***APC|SOX9|INPP4B|TP53||PIM1|*** | ***negative|TC<1% IC<1%*** | ***4.74*** | ***MSS*** |
| ***198*** | ***High 18,44%*** | ***METASTATIC LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|*** | ***negative|TPS<1%*** | ***9.46*** | ***MSS*** |
| ***199*** | ***45*** | ***OVARIAN*** | ***-*** | ***-*** | ***Negative*** | ***-*** | ***3.8*** | ***MSS*** |
| ***200*** | ***19*** | ***OVARIAN*** | ***-*** | ***-*** | ***TP53*** | ***-*** | ***3.8*** | ***MSS*** |
| ***201*** | ***High 22%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|*** |  | ***4.74*** | ***MSS*** |
| ***202*** | ***High 39%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***MUTYH|TP53|*** |  | ***4.74*** | ***MSS*** |
| ***203*** | ***High 39.86%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***Negative*** |  | ***1.9*** | ***MSS*** |
| ***204*** | ***High 16,9%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***205*** | ***High 27,31%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|GATA3|*** | ***positive|TC 10%, IC 20%*** |  | ***MSS*** |
| ***206*** | ***High 34.83 %*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***PTPRT|*** | ***negative|TC<1% IC <1%*** | ***7.59*** | ***MSS*** |
| ***207*** | ***High 35.42 %*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC 15% IC 5%*** | ***5.71*** | ***MSS*** |
| ***208*** | ***High 44%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|*** |  | ***3.8*** | ***MSS*** |
| ***209*** | ***High 46,06%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|PIK3CA|MECOM*** | ***positive|TC<1%, IC 30%*** | ***1.96*** | ***MSS*** |
| ***210*** | ***High 48,02%*** | ***PROSTATE CANCER*** | ***-*** | ***-*** | ***KRAS|CCNE1|*** | ***negative|TC<1%, IC<1%*** | ***10.41*** | ***MSS*** |
| ***211*** | ***High 27,08%*** | ***RECTUM CANCER*** | ***-*** | ***-*** | ***NRAS|MUTYH|MUTYH|BRAF|APC|FBXW7|TP53|TP53*** | ***negative|TC<1%, IC<1%*** | ***27.79*** | ***MSS*** |
| ***212*** | ***Low 0%*** | ***METASTATIC PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***positive|TC<1% IC 2%*** | ***0*** | ***MSS*** |
| ***213*** | ***Low 1.59 %*** | ***METASTATIC PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC 25% IC <1%*** | ***5.69*** | ***MSS*** |
| ***214*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***2.85*** | ***MSS*** |
| ***215*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***CDKN2A|KRAS*** | ***negative|TC<1%, IC<1%*** | ***0.97*** | ***MSS*** |
| ***216*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***negative|TC<1%, IC<1%*** | ***4.77*** | ***MSS*** |
| ***217*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC<1% IC<1%*** | ***3.83*** | ***MSS*** |
| ***218*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC<1% IC<1%*** | ***3.8*** | ***MSS*** |
| ***219*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4|CDKN2A|TP53|IKBKB|*** | ***negative|TC<1% IC<1%*** | ***5.71*** | ***MSS*** |
| ***220*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***negative|TC<1%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***221*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS*** | ***negative|TC<1%, IC<1%*** | ***6.62*** | ***MSS*** |
| ***222*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|H3C2*** | ***negative|TC<1%, IC<1%*** | ***4.73*** | ***MSS*** |
| ***223*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|CDC73|RBM10|CDKN1A|*** | ***positive|TC<1%, IC 5%*** | ***5.71*** | ***MSS*** |
| ***224*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|SMAD4|CDKN2A|*** | ***positive|TC 5%, IC<1%*** | ***4.75*** | ***MSS*** |
| ***225*** | ***Low 0%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53*** | ***negative|TC<1%, IC<1%*** | ***1.9*** | ***MSS*** |
| ***226*** | ***Low 0,79%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|SMAD4|TGFBR2|*** | ***negative|TC<1%, IC<1%*** | ***3.8*** | ***MSS*** |
| ***227*** | ***Low 1.24 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC 1% IC<1%*** | ***2.85*** | ***MSS*** |
| ***228*** | ***Low 1.64 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|CCNE1|AKT2|AXL|*** | ***negative|TC <1% IC <1%*** | ***1.9*** | ***MSS*** |
| ***229*** | ***Low 2,19%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|SMAD4|TGFBR2|*** | ***negative|TC<1%, IC<1%*** | ***4.74*** | ***MSS*** |
| ***230*** | ***Low 2,39%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC 10%, IC<1%*** | ***3.81*** | ***MSS*** |
| ***231*** | ***Low 2.42 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC <1% IC<1%*** | ***0.95*** | ***MSS*** |
| ***232*** | ***Low 3,64%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC<1% IC 2%*** | ***4.93*** | ***MSS*** |
| ***233*** | ***Low 5.33 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|RNF43|TP53|*** | ***negative|TC <1% IC<1%*** | ***1.91*** | ***MSS*** |
| ***234*** | ***Low 5,52%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***positive|TC 10%, IC 1%*** | ***5.7*** | ***MSS*** |
| ***235*** | ***Low 5.74 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|MPL|TP63|AR|*** | ***negative|TC <1% IC<1%*** | ***4.76*** | ***MSS*** |
| ***236*** | ***Low 6.69 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC <1% IC<1%*** | ***4.73*** | ***MSS*** |
| ***237*** | ***Low 7,61%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53*** | ***negative|TC<1%, IC<1%*** | ***2.85*** | ***MSS*** |
| ***238*** | ***Low 7,75%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***negative|TC<1%, IC<1%*** | ***1.9*** | ***MSS*** |
| ***239*** | ***Low 8,65%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|FGFR3 fusion|*** | ***positive|TC 30%, IC 5%*** | ***2.85*** | ***MSS*** |
| ***240*** | ***Low 9,41%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC 2%, IC<1%*** | ***1.99*** | ***MSS*** |
| ***241*** | ***Low 9.58 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|CDKN2A|*** | ***negative|TC <1% IC<1%*** | ***2.84*** | ***MSS*** |
| ***242*** | ***Low 10,09%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|PIK3CA|MECOM|*** | ***positive|TC<1%, IC 2%*** | ***4.79*** | ***MSS*** |
| ***243*** | ***Low 11,06%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***RAD51|KRAS|TP53|*** | ***negative|TC<1%, IC<1%*** | ***6.64*** | ***MSS*** |
| ***244*** | ***Low 11.11 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|TGFBR2|RASA2*** | ***-|*** | ***4.73*** | ***MSS*** |
| ***245*** | ***Low 12,33%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|ERBB2|KRAS|NTRK3*** | ***negative|TC<1%, IC<1%*** | ***4.79*** | ***MSS*** |
| ***246*** | ***Low 13.64 %*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***negative|TC <1% IC<1%*** | ***2.85*** | ***MSS*** |
| ***247*** | ***Low 15,76%*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|DPYD|TP53|*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***248*** | ***Low 6.35*** | ***PANCREATIC CANCER*** | ***-*** | ***-*** | ***KRAS|*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***249*** | ***Low 11,56%*** | ***ADENOID CYSTIC CARCINOMA*** | ***-*** | ***-*** | ***PTCH1*** | ***negative|CPS <1, TPS<1%*** | ***3.81*** | ***MSS*** |
| ***250*** | ***Low 4,8%*** | ***AMPULLA OF VATER CARCINOMA*** | ***-*** | ***-*** | ***RB1|CTNNB1|TP53|CCNE1|*** | ***negative|TC<1% IC<1%*** | ***8.7*** | ***MSS*** |
| ***251*** | ***Low 0%*** | ***Biliary tract cancer*** | ***-*** | ***-*** | ***Negative*** | ***unknown negative|TC<1%, IC<1%*** | ***1.89*** | ***MSS*** |
| ***252*** | ***Low 0%*** | ***Ca χοληδόχου κύστης*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***1.94*** | ***MSS*** |
| ***253*** | ***Low 14.46 %*** | ***DESMOPLASTIC SMALL ROUND CELL TUMOR*** | ***-*** | ***-*** | ***DPYD|*** | ***positive|TC <1% IC 3%*** | ***2.86*** | ***MSS*** |
| ***254*** | ***Low 0%*** | ***EPITHELIOD HEMANGIOENDOTHELIOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1%, IC<1%*** | ***1.9*** | ***MSS*** |
| ***255*** | ***Low 11,09%*** | ***ESOPHAGEAL CANCER*** | ***-*** | ***-*** | ***CDK6|CUL4B|*** | ***positive|CPS 10*** | ***7.58*** | ***MSS*** |
| ***256*** | ***Low 5,72%*** | ***GALL BLADDER CANCER*** | ***-*** | ***-*** | ***TP53|EIF1AX*** | ***negative|TC<1%, IC<1%*** | ***2.92*** | ***MSS*** |
| ***257*** | ***Low 3.81 %*** | ***HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA*** | ***-*** | ***-*** | ***CDKN2A|FBXW7|PARP2|TP53|TP53|ERBB2|CUL4A|*** | ***positive|CPS 24 TPS<1%*** | ***7.6*** | ***MSS*** |
| ***258*** | ***Low 2,55%*** | ***MERKEL CELL CARCINOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|*** | ***0.95*** | ***MSS*** |
| ***259*** | ***Low 8,12%*** | ***Metastatic Melanoma*** | ***-*** | ***-*** | ***GNAQ|NRAS|SF3B1|*** | ***positive|TC<1% IC 10%*** | ***4.75*** | ***MSS*** |
| ***260*** | ***Low 1.99 %*** | ***METASTATIC THYROID CANCER*** | ***-*** | ***-*** | ***NRAS|*** | ***negative|TC<1% IC<1%*** | ***4.75*** | ***MSS*** |
| ***261*** | ***Low 2,5%*** | ***PAPILLARY THYROID CANCER*** | ***-*** | ***-*** | ***BRAF|*** | ***negative|TC<1%, IC<1%*** | ***6.68*** | ***MSS*** |
| ***262*** | ***Low 0%*** | ***PEComa*** | ***-*** | ***-*** | ***TP53|*** | ***negative|TC<1%, IC<1%*** | ***6.64*** | ***-*** |
| ***263*** | ***Low 2.71 %*** | ***PENILE CANCER*** | ***-*** | ***-*** | ***CDKN2A|FAT1|TERT|TP53|TP53|*** | ***positive|TC <1% IC 2%*** | ***4.74*** | ***MSS*** |
| ***264*** | ***Low 0%*** | ***THYROID CANCER*** | ***-*** | ***-*** | ***BRAF|PIK3CA*** | ***positive|TC>50%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***265*** | ***Low 0%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***FANCE|TP53|EGFR fusion|PRKACA|MYC|CDK6*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***266*** | ***Low 0 %*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***TP53|*** |  | ***5.69*** | ***MSS*** |
| ***267*** | ***Low 0,84%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***TP53|FAT1|*** | ***negative|TC<1%, IC<1%*** | ***4.74*** | ***MSS*** |
| ***268*** | ***Low 1,04%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***KRAS|TP53|CCNE1*** | ***positive|TC 30%, IC<1%*** | ***7.56*** | ***MSS*** |
| ***269*** | ***Low 11,26%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***BRAF|TP53|SMAD4|FAS|ARID2|*** | ***negative|TC<1%, IC<1%*** | ***4.75*** | ***MSS*** |
| ***270*** | ***Low 12,68%*** | ***UNKNOWN PRIMARY*** | ***-*** | ***-*** | ***KRAS|TP53|CREBBP|*** | ***positive|CPS >70*** | ***4.47*** | ***MSS*** |
| ***271*** | ***Low 5,06%*** | ***Neurofibrosarcoma*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***2.86*** | ***MSS*** |
| ***272*** | **Low 0%** | ***LIVER CANCER*** | **-** | **-** | **TP53|** |  | **6.65** | **MSS** |
| ***273*** | **Low 7,28%** | ***LIVER CANCER*** | **-** | **-** | **FGFR3 fusion|MDM2|FGFR3|CCNE1|MECOM|NSD2** | **negative|TC<1%, IC<1%** | **2.87** | **MSS** |
| ***274*** | ***Low 0.59 %*** | ***RENAL CANCER*** | ***-*** | ***-*** | ***MSH3|*** |  | ***3.86*** | ***MSS*** |
| ***275*** | ***Low 3,2%*** | ***RENAL CANCER*** | ***-*** | ***-*** | ***SETD2|*** |  | ***6.69*** | ***MSS*** |
| ***276*** | ***Low 2.29 %*** | ***EWING SARCOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***0.95*** | ***MSS*** |
| ***277*** | ***Low 0 %*** | ***GLIOSARCOMA*** | ***-*** | ***-*** | ***PTEN|*** | ***positive|TC<1% IC 1%*** | ***1.9*** | ***MSS*** |
| ***278*** | ***Low 14,02%*** | ***LEIOMYOSARCOMA*** | ***-*** | ***-*** | ***TP53|TSHR|*** | ***negative|TC<1%, IC<1%*** | ***4.74*** | ***MSS*** |
| ***279*** | ***Low 0%*** | ***LIPOSARCOMA*** | ***-*** | ***-*** | ***CDK4|MDM2|*** | ***negative|TC<1%, IC<1%*** | ***1.91*** | ***MSS*** |
| ***280*** | ***Low 14.35 %*** | ***LIPOSARCOMA*** | ***-*** | ***-*** | ***CREBBP|MDM2|CDK4|CTNND2|SDHA|STAT6|EIF1AX|*** | ***positive|TC 20% IC 5%*** | ***2.85*** | ***MSS*** |
| ***281*** | ***Low 1,53%*** | ***Myxoid Chondrosarcoma*** | ***-*** | ***-*** | ***Negative*** | ***negative|TPS<1%*** | ***1.93*** | ***MSS*** |
| ***282*** | ***Low 5.47 %*** | ***SARCOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***0*** | ***MSS*** |
| ***283*** | ***Low 7,84%*** | ***SARCOMA*** | ***-*** | ***-*** | ***MDM2|CDK4|*** | ***-|*** | ***1.9*** | ***MSS*** |
| ***284*** | ***Low 0 %*** | ***SYNOVIAL SARCOMA-*** | ***-*** | ***-*** | ***Negative*** | ***positive|TC<1% IC 10%*** | ***0.94*** | ***MSS*** |
| ***285*** | ***Low 0%*** | ***BLADDER CANCER*** | ***-*** | ***-*** | ***Negative*** | ***positive|CPS 11,7*** | ***6.62*** | ***MSS*** |
| ***286*** | ***Low 9,65%*** | ***BLADDER CANCER*** | ***-*** | ***-*** | ***TP53|PBRM1|CTNNB1|MET|PIK3CG|*** | ***negative|TC<1%, IC<1%*** | ***3.8*** | ***MSS*** |
| ***287*** | ***Low 14,62%*** | ***BRAIN CANCER*** | ***-*** | ***-*** | ***SLX4|FGFR3 fusion|*** | ***negative|TC<1%, IC<1%*** | ***2.89*** | ***MSS*** |
| ***288*** | ***Low 15,31%*** | ***BRAIN CANCER*** | ***-*** | ***-*** | ***PIK3CA|EGFR fusion|EGFR|MDM4|PIK3C2B|*** | ***positive|TC 2%, IC 10%*** | ***5.81*** | ***MSS*** |
| ***289*** | ***Low 5,57%*** | ***Brain Tumor*** | ***-*** | ***-*** | ***IDH1|IDH1|FUBP1|TERT*** | ***negative|TC<1% IC<1%*** | ***7.72*** | ***MSS*** |
| ***290*** | ***Low 8,59%*** | ***Brain Tumor*** | ***-*** | ***-*** | ***TERT|FBXW7|*** | ***negative|TC<1% IC<1%*** | ***6.65*** | ***MSS*** |
| ***291*** | ***Low 9,76%*** | ***BRAIN TUMOR*** | ***-*** | ***-*** | ***NF1|TERT|FGFR3 fusion|*** | ***positive|TC<20%, IC 2%*** | ***2.85*** | ***MSS*** |
| ***292*** | ***Low 13.58 %*** | ***BRAIN TUMOR*** | ***-*** | ***-*** | ***TERT|EGFR fusion|EGFR|AKT3|CDK4|WT1||*** | ***positive|TC 10% IC10%*** | ***5.69*** | ***MSS*** |
| ***293*** | ***Low 0%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|CPS<1*** | ***5.69*** | ***MSS*** |
| ***294*** | ***Low 7,69%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***Negative*** |  | ***2.86*** | ***MSS*** |
| ***295*** | ***Low 7,88%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***Negative*** |  | ***5.68*** | ***MSS*** |
| ***296*** | ***Low 10,81%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***FGFR1|*** | ***-|CPS <1*** | ***1.92*** | ***MSS*** |
| ***297*** | ***Low 12,78%*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***EMSY|*** | ***negative|IC<1%*** | ***2.85*** | ***MSS*** |
| ***298*** | ***Low 13.51 %*** | ***BREAST CANCER*** | ***-*** | ***-*** | ***ESR1|ESR1|FGFR1|IKBKB|CCND1|FGF19|FGF4|FGF3|*** |  | ***2.84*** | ***MSS*** |
| ***299*** | ***Low 7,97%*** | ***Ca COLON*** | ***-*** | ***-*** | ***MSH2|ERBB2|RNF43|SDHA|TP53|CREBBP||*** | ***positive|TC<1% IC 20%*** | ***66.26*** | ***MSIH*** |
| ***300*** | ***Low 13.05 %*** | ***CERVICAL CANCER*** | ***-*** | ***-*** | ***FGFR3|KMT2D|CCND1|MDM2|*** | ***negative|CPS<1*** | ***4.76*** | ***MSS*** |
| ***301*** | ***Low 0,55%*** | ***CHOLANGIOCACINOMA*** | ***-*** | ***-*** | ***PIK3CA|KEAP1|*** | ***negative|TC<1%, IC<1%*** | ***2.83*** | ***MSS*** |
| ***302*** | ***Low 0%*** | ***Cholangiocarcinoma*** | ***-*** | ***-*** | ***KRAS|TP53|*** | ***positive|TC<1% IC 2%*** | ***1.9*** | ***MSS*** |
| ***303*** | ***Low 0%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1|IDH1|*** | ***negative|TC<1% IC<1%*** | ***1.9*** | ***MSS*** |
| ***304*** | ***Low 0%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***TP53|FGF19|FGF4|CCND1|FGF3*** | ***negative|TC<1%, IC<1%*** | ***3.85*** | ***MSS*** |
| ***305*** | ***Low 0%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***ELF3|FGF4|EGFR|TP53|*** | ***negative|TC<1%, IC<1%*** | ***13.37*** | ***MSS*** |
| ***306*** | ***Low 1.8 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***IDH1*** | ***negative|TC <1% IC<1%*** | ***3.79*** | ***MSS*** |
| ***307*** | ***Low 8,44*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***4.77*** | ***MSS*** |
| ***308*** | ***Low 10.85 %*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***KRAS|KMT2D|PRKACA fusion|CDK6|MDM2*** | ***positive|TC 10% IC<1%*** | ***11.47*** | ***MSS*** |
| ***309*** | ***Low 14,02%*** | ***CHOLANGIOCARCINOMA*** | ***-*** | ***-*** | ***PIK3CA|*** | ***negative|TC<1%, IC<1%*** | ***2.84*** | ***MSS*** |
| ***310*** | ***Low 0%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***SOX9||*** | ***negative|TC<1%, IC<1%*** | ***6.66*** | ***MSS*** |
| ***311*** | ***Low 0%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|PIK3CA|PIK3CA|SMAD4|APC|APC|SOX9|*** |  | ***5.73*** | ***MSS*** |
| ***312*** | ***Low 0 %*** | ***COLON CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|PIK3CA|PIK3CA|APC|TBX3|*** | ***positive|TC 5% IC<1%*** | ***8.5*** | ***MSS*** |
| ***313*** | ***Low 7,93%*** | ***COLON CANCER*** | ***-*** | ***-*** | ***PIK3CA|PIK3CA|KRAS|KRAS|MTOR|APC|ELF3|*** | ***negative|TC<1%, IC<1%*** | ***5.69*** | ***MSS*** |
| ***314*** | ***Low 11.03 %*** | ***COLON CANCER*** | ***-*** | ***-*** | ***APC|APC|TP53|*** | ***positive|TC<1% IC 20%*** | ***9.49*** | ***MSS*** |
| ***315*** | ***Low 0%*** | ***Colorectal Cancer*** | ***-*** | ***-*** | ***KRAS|KRAS|SMAD4|PIK3CA|PIK3CA*** | ***negative|TC<1% IC<1%*** | ***7.08*** | ***MSS*** |
| ***316*** | ***Low 4,39%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|PIK3CA|PIK3CA|APC|FBXW7|*** | ***positive|TC<1%, IC 5%*** | ***3.8*** | ***MSS*** |
| ***317*** | ***Low 5,81%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***APC|APC|KRAS|KRAS|TP53|*** | ***negative|TC<1%, IC<1%*** | ***3.84*** | ***MSS*** |
| ***318*** | ***Low 9,48%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***APC|TP53|*** | ***positive|TC<1% IC 30%*** | ***2.84*** | ***MSS*** |
| ***319*** | ***Low 14,43%*** | ***COLORECTAL CANCER*** | ***-*** | ***-*** | ***NRAS|APC|APC|BRAF|TP53*** | ***negative|*** | ***4.81*** | ***MSS*** |
| ***320*** | ***Low 0%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***MLH1|PIK3R2|PIK3R2|ZFHX3|RB1|*** | ***positive|TC 30%, IC 20%*** | ***24.66*** | ***MSIH*** |
| ***321*** | ***Low 4,69%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***FANCC|TP53|FBXW7|*** | ***positive|TC 2%, IC 30%*** | ***5.69*** | ***MSS*** |
| ***322*** | ***Low 6,32%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***AKT1|*** | ***negative|TC<1%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***323*** | ***Low 11,45%*** | ***ENDOMETRIAL CANCER*** | ***-*** | ***-*** | ***TP53*** | ***negative|TC<1% IC<1%*** | ***3.81*** | ***MSS*** |
| ***324*** | ***Low 3.69 %*** | ***ENDOMETRIAL SARCOMA*** | ***-*** | ***-*** | ***ESR1|*** |  | ***1.9*** | ***MSS*** |
| ***325*** | **Low 0%** | **Gastric Cancer** | **-** | **-** | ***Negative*** | **positive|CPS 2%** | **2.88** | **MSS** |
| ***326*** | **Low 0%** | **GASTRIC CANCER** | **-** | **-** | **KRAS|** | **positive|CPS 48,5** | **1.93** | **-** |
| ***327*** | **Low 0%** | **GASTRIC CANCER** | **-** | **-** | **MET|** | **positive|CPS 38** | **2.89** | **MSS** |
| ***328*** | **Low 2.12 %** | **GASTRIC CANCER** | **-** | **-** | **TP53|EGFR|CCND3|** | **positive|CPS 7** | **5.76** | **MSS** |
| ***329*** | **Low 4,25%** | **GASTRIC CANCER** | **-** | **-** | ***Negative*** | **positive|CPS 13** | **6.63** | **MSS** |
| ***330*** | **Low 5,91%** | **GASTRIC CANCER** | **-** | **-** | **PIK3CA|TP53|EGFR|** | **negative|CPS<1** | **12.39** | **MSS** |
| ***331*** | **Low 6.8 %** | **GASTRIC CANCER** | **-** | **-** | **CDH1|TGFBR2|** | **positive|CPS 10,83** | **2.84** | **MSS** |
| ***332*** | **Low 15,6%** | **GASTRIC CANCER** | **-** | **-** | **TP53|ZFHX3|EIF1AX|ERCC1|BRCA1|** | **positive|CPS 32** | **2.01** | **MSS** |
| ***333*** | **Low 0%** | **GASTROESOPHAGEAL CANCER** | **-** | **-** | **KRAS|SMAD4|TP53|FANCG|** | **positive|CPS 21** | **3.79** | **MSS** |
| ***334*** | **Low 14.16 %** | **GASTROINTESTINAL STROMAL TUMOR** | **-** | **-** | **KIT|MSH3** | **negative|TC <1% IC<1%** | **2.84** | **MSS** |
| ***335*** | ***Low 0%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***EGFR fusion|EGFR|EIF1AX |MDM2|BCL2L12|CCND2|RIT1|*** | ***positive|TC<1%, IC 5%*** | ***0.96*** | ***MSS*** |
| ***336*** | ***Low 5,03%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***PTEN|TERT|*** | ***negative|TC<1%, IC<1%*** | ***1.9*** | ***MSS*** |
| ***337*** | ***Low 6,19%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***NF1|NF1|FANCI|HNF1A|PTEN|TERT|PTPN11|*** | ***positive|TC >50% IC 10%*** | ***9.46*** | ***MSS*** |
| ***338*** | ***Low 6,94%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***TERT|EGFR fusion|EGFR|*** | ***positive|TC<1%, IC<1%*** | ***1.89*** | ***MSS*** |
| ***339*** | ***Low 7,99%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***TERT|MDM4|PIK3C2B|*** | ***negative|TC<1%, IC<1%*** | ***2.84*** | ***MSS*** |
| ***340*** | ***Low 8.02 %*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***PIK3CA|PIK3CA|CDKN2A|NF1|TERT|*** | ***negative|TC <1% IC<1%*** | ***4.74*** | ***MSS*** |
| ***341*** | ***Low 8,95%*** | ***Glioblastoma*** | ***-*** | ***-*** | ***TERT|PTEN|EGFR|SDHB*** | ***positive|TC 5%, IC<1%*** | ***6.68*** | ***MSS*** |
| ***342*** | ***Low 12,2*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***EGFR|CREBBP|SETD2|TERT|EGFR|*** | ***negative|TC<1% IC<1%*** | ***7.58*** | ***MSS*** |
| ***343*** | ***Low 14,29%*** | ***GLIOBLASTOMA*** | ***-*** | ***-*** | ***EGFR fusion|EGFR|MDM4|PIK3C2B|*** | ***positive|TC 10%, IC<1%*** | ***0.95*** | ***MSS*** |
| ***344*** | ***Low 0%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***NF1|TP53|*** | ***negative|TPS<1%*** | ***7.65*** | ***MSS*** |
| ***345*** | ***Low 0%*** | ***Lung Cancer*** | ***-*** | ***-*** | ***NUTM1 fusion|*** | ***negative|TPS<1%*** | ***2.85*** | ***MSS*** |
| ***346*** | ***Low 0%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***Negative*** |  | ***0.98*** | ***MSS*** |
| ***347*** | ***Low 0 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|BRAF|ARID2|GNAS|*** | ***negative|TPS<1%*** | ***1.89*** | ***MSS*** |
| ***348*** | ***Low 0%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***EGFR|TP53|*** | ***negative|TPS<1%*** | ***3.79*** | ***MSS*** |
| ***349*** | ***Low 0%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|TPS<1%*** | ***1.9*** | ***MSS*** |
| ***350*** | ***Low 1,73%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|U2AF1|*** | ***negative|IC<2%*** | ***1.9*** | ***MSS*** |
| ***351*** | ***Low 5,74%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***Negative*** | ***positive|TPS 90%*** | ***1.89*** | ***MSS*** |
| ***352*** | ***Low 6,46%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***CDK4|KRAS|TP53|YES1|*** | ***negative|TPS<1%*** | ***8.81*** | ***MSS*** |
| ***353*** | ***Low 6,78%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***TP53|CDH10|*** | ***positive|TPS>50%*** | ***6.71*** | ***MSS*** |
| ***354*** | ***Low 6.97 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***ALK fusion|*** | ***positive|TPS 20%*** | ***1.89*** | ***MSS*** |
| ***355*** | ***Low 7,48%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***Negative*** | ***negative|TPS<1%*** | ***4.74*** | ***MSS*** |
| ***356*** | ***Low 8.65 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|SETD2|*** | ***negative|TPS<1%*** | ***14.25*** | ***MSS*** |
| ***357*** | ***Low 10%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***PMS1|XRCC2|TP53|SMARCA4|*** | ***negative|TPS<1%*** | ***21.85*** | ***MSS*** |
| ***358*** | ***Low 12,74%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|MEN1*** | ***negative|TPS<1%*** | ***8.53*** | ***MSS*** |
| ***359*** | ***Low 13,6%*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***IDH1|RBM10|AURKA|*** | ***positive|TPS>50%*** | ***11.37*** | ***MSS*** |
| ***360*** | ***Low 14.17 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|KRAS|SMARCA4|*** | ***negative|TPS<1%*** | ***4.74*** | ***MSS*** |
| ***361*** | ***Low 14,63*** | ***Lung Cancer*** | ***-*** | ***-*** | ***TP53|MAP2K1|DICER1|*** | ***negative|TPS<1%*** | ***17.37*** | ***MSS*** |
| ***362*** | ***Low 15.02 %*** | ***LUNG CANCER*** | ***-*** | ***-*** | ***MUTYH|APC|*** | ***negative|TPS <1%*** | ***1.93*** | ***MSS*** |
| ***363*** | ***Low 12.91 %*** | ***METASTATIC BREAST CANCER*** | ***-*** | ***-*** | ***ESR1|ESR1|KMT2C|ARID2|ACVR2A|FGF19|*** | ***-|CPS 7,3*** | ***16.19*** | ***MSS*** |
| ***364*** | ***Low 15%*** | ***Metastatic Breast Cancer*** | ***-*** | ***-*** | ***KRAS|BRAF|TP53|*** | ***negative|TC<1% IC<1%*** | ***3.79*** | ***MSS*** |
| ***365*** | ***Low 6.67 %*** | ***METASTATIC LUNG CANCER*** | ***-*** | ***-*** | ***KRAS|STK11|STK11|MCL1|*** | ***negative|TPS<1%*** | ***15.22*** | ***MSS*** |
| ***366*** | ***Low 12,04%*** | ***OLIGODENDROGLIOMA*** | ***-*** | ***-*** | ***IDH2|IDH2|IDH2|CIC|ARID2|TERT|*** | ***negative|TC<1%, IC<1%*** | ***3.82*** | ***MSS*** |
| ***367*** | **Low 0%** | **OSTEORASCOMA** | **-** | **-** | ***Negative*** | **negative|TC<1%, IC<1%** | **5.77** | **MSS** |
| ***368*** | ***Low 0%*** | ***Ovarian Cancer*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1% IC<1%*** | ***3.89*** | ***MSS*** |
| ***369*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***TP53|TP53|*** | ***negative|TC<1%, IC<1%*** | ***5.73*** | ***MSS*** |
| ***370*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***Negative*** |  | ***4.81*** | ***MSS*** |
| ***371*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***KRAS|PIK3CA|SMAD4|TP53*** | ***positive|TC<1%, IC 10%*** | ***4.74*** | ***MSS*** |
| ***372*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***NF1|TP53|YAP1|CTLA4|H3C2|*** | ***positive|TC 2%, IC 40%*** | ***8.54*** | ***MSS*** |
| ***373*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***KRAS|PIK3CA|DPYD|PPP2R1A|DDR2|H3C2|CIITA|*** | ***positive|TC<1%, IC 2%*** | ***1.9*** | ***MSS*** |
| ***374*** | ***Low 0%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***KRAS|PIK3CA|*** | ***negative|TC<1%, IC<1%*** | ***6.67*** | ***MSS*** |
| ***375*** | ***Low 5,01%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***EP300|TP53*** | ***negative|TC<1% IC<1%*** | ***10.45*** | ***MSS*** |
| ***376*** | ***Low 15,21%*** | ***OVARIAN CANCER*** | ***-*** | ***-*** | ***ARID1B|KRAS|AKT2|PIK3R2|IKBKB*** | ***positive|TC 2% IC 30%*** | ***4.83*** | ***MSS*** |
| ***377*** | ***Low 0%*** | ***OVARIAN IMMATURE TERATOMA*** | ***-*** | ***-*** | ***Negative*** | ***negative|TC<1%, IC<1%*** | ***2.85*** | ***MSS*** |
| ***378*** | ***Low 1,62%*** | ***PROSTATE CANCER*** | ***-*** | ***-*** | ***CDK12|CDK12|CDK12|CDK12|FOXA1|AR|MYC|GATA2|MDM4|PIK3C2B|*** | ***negative|TC<1%, IC<1%*** | ***6.63*** | ***MSS*** |
| ***379*** | ***Low 8,79%*** | ***PROSTATE CANCER*** | ***-*** | ***-*** | ***XRCC3|XRCC3|FGFR2|MPL|MYCL|*** | ***positive|TC<1%, IC 2%*** | ***4.76*** | ***MSS*** |
| ***380*** | ***Low 9,48%*** | ***PROSTATE CANCER*** | ***-*** | ***-*** | ***ERG fusion|*** | ***negative|TC<1% IC<1%*** | ***5.74*** | ***MSS*** |
| ***381*** | ***Low 13.33 %*** | ***PROSTATE CANCER*** | ***-*** | ***-*** | ***MYC|CSMD3|*** | ***negative|TC<1% IC<1%*** | ***4.73*** | ***MSS*** |
| ***382*** | ***Low 0%*** | ***UROTHELIAL CANCER*** | ***-*** | ***-*** | ***KDM5C|MDM2|CDK4|FGF19|FGF4|CCND1|MCL1|*** |  | ***2.85*** | ***MSS*** |
| ***383*** | ***Low 0 %*** | ***UROTHELIAL CANCER*** | ***-*** | ***-*** | ***PBRM1|MDM2|TBX3|YES1|BCL2L12*** | ***positive|IC 25%*** | ***14.21*** | ***MSS*** |
| ***384*** | ***Low 8,12%*** | ***UROTHELIAL CARCINOMA*** | ***-*** | ***-*** | ***NF2|TP53*** | ***positive|IC 10%*** | ***7.68*** | ***MSS*** |
| ***385*** | ***Low 0%*** | ***Cholangiocarcinoma*** | ***-*** | ***-*** | ***KRAS|TP53|MYC|*** | ***negative|TC<1%, IC<1%*** | ***3.79*** | ***MSS*** |
| ***386*** | ***High 34,47*** | ***PANCREATIC CANCER*** | ***+*** | ***+*** | ***BRCA2|NBN|SMAD4|*** | ***negative|TC<1% , IC<1%*** | ***6.63*** | ***MSS*** |
| ***387*** | ***High 27.32 %*** | ***ADRENAL GLAND METASTATIC CANCER*** | ***+*** | ***-*** | ***BRCA2|*** | ***negative|TC<1% IC<1%*** | ***0.96*** | ***MSS*** |
| ***388*** | ***High 35.89 %*** | ***TUBA CARCINOMA*** | ***+*** | ***-*** | ***BRCA1|TP53|ESR1 fusion*** | ***positive|TC <1% IC 5%*** | ***7.63*** | ***MSS*** |
| ***389*** | ***High 28,08%*** | ***UNKNOWN PRIMARY*** | ***+*** | ***-*** | ***BRCA1|TP53|FAT1*** | ***negative|TC<1% IC<1%*** | ***4.76*** | ***MSS*** |
| ***390*** | ***Low 0%*** | ***UNKNOWN PRIMARY*** | ***+*** | ***-*** | ***BRCA2|KRAS|TP53|CCNE1*** | ***positive|TC 20%, IC<1%*** | ***1.9*** | ***MSS*** |
| ***391*** | ***High 39.73 %*** | ***BREAST CANCER*** | ***+*** | ***-*** | ***BRCA2|BRCA2|TP53|TNFAIP3|JAK2|CD274|PDCD1LG2|*** |  | ***1.9*** | ***MSS*** |
| ***392*** | ***High 45,56%*** | ***BREAST CANCER*** | ***+*** | ***-*** | ***BRCA2|BRCA2|*** | ***-|CPS <1*** | ***5.67*** | ***MSS*** |
| ***393*** | ***High 49,52%*** | ***Breast Cancer*** | ***+*** | ***-*** | ***BRCA1|BRCA1|TP53*** | ***positive|CPS 4,5*** | ***7.59*** | ***MSS*** |
| ***394*** | ***Low 14.93 %*** | ***CHOLANGIOCARCINOMA*** | ***+*** | ***-*** | ***BRCA1|MAPK1|TP53|KMT2D|MYC*** | ***negative|TC <1% IC<1%*** | ***1.9*** | ***MSS*** |
| ***395*** | ***High 21,73%*** | ***COLON CANCER*** | ***+*** | ***-*** | ***BRCA2|BRAF|BRAF|TP53|CTLA4||*** |  | ***4.74*** | ***MSS*** |
| ***396*** | ***Low 14,48%*** | ***COLON CANCER*** | ***+*** | ***-*** | ***BRCA2|KRAS|KRAS|TP53|APC|APC|SETD2|*** | ***positive|TC<1%, IC 2%*** | ***10.43*** | ***MSS*** |
| ***397*** | ***Low 15.35 %*** | ***COLON CANCER*** | ***+*** | ***-*** | ***BRCA2|APC|APC|RAF1|MAP2K1|TP53||*** | ***positive|TC<1% IC 10%*** | ***4.73*** | ***MSS*** |
| ***398*** | ***High 69.24 %*** | ***ENDOMETRIAL STROMAL SARCOMA*** | ***+*** | ***-*** | ***BRCA2|NF1|*** | ***negative|TC<1% IC<1%*** | ***3.81*** | ***-*** |
| ***399*** | ***High 27,86%*** | ***LUNG CANCER*** | ***+*** | ***-*** | ***EGFR|BRCA1|NF1|RBM10|*** | ***negative|TPS<1%*** | ***6.65*** | ***MSS*** |
| ***400*** | ***Low 0%*** | ***LUNG CANCER*** | ***+*** | ***-*** | ***BRCA2|TP53|*** | ***negative|TPS<1%*** | ***3.83*** | ***MSS*** |
| ***401*** | ***High 26.62 %*** | ***METASTATIC COLON CANCER*** | ***+*** | ***-*** | ***KRAS|KRAS|BRCA2|APC*** | ***negative|TC<1% IC<1%*** | ***11.37*** | ***MSS*** |
| ***402*** | ***27*** | ***OVARIAN*** | ***+*** | ***-*** | ***BRCA1,TP53*** | ***-*** |  |  |
| ***403*** | ***High 28%*** | ***OVARIAN CANCER*** | ***+*** | ***-*** | ***BRCA2|TP53|TP53|MYCL|CCNE1|KRAS|MPL|*** |  | ***5.7*** | ***MSS*** |
| ***404*** | ***High 32.7 %*** | ***OVARIAN CANCER*** | ***+*** | ***-*** | ***BRCA1|TP53*** | ***positive|TC <1% IC 5%*** | ***4.75*** | ***MSS*** |
| ***405*** | ***High 39,61%*** | ***OVARIAN CANCER*** | ***+*** | ***-*** | ***BRCA1|MUTYH|TP53|*** | ***positive|TC 30%, IC<5%*** | ***3.81*** | ***MSS*** |
| ***406*** | ***High 42,14%*** | ***OVARIAN CANCER*** | ***+*** | ***-*** | ***BRCA1|TP53|CREBBP|SOX9|DNMT3A|MECOM|IL7R|CSMD3|HDAC9|TP63|*** | ***negative|TC<1%, IC<1%*** | ***4.76*** | ***MSS*** |